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ABSTRACT  
This mini review presents the current trends and topical issues on interferon. This article illustrates the theoretical background and details 
about interferon, its mechanism of action or roles in the prevention of microbial- or pathogenic disease progression, types and classes, and their 
therapeutic potentials. All the reported applications have shown that interferon has found its application in gene manipulation and expression 
of gene products; immunological techniques, viral disease treatment and in the treatment of cancers.  
Keywords: Interferon, cancers, cancer therapy, viral infection, viral disease treatment. 
 
Article Info: Received 06 March 2020;     Review Completed 21 April 2020;     Accepted 27 April 2020;     Available online 15 May 2020 
Cite this article as: 
Uchendu IK, Ojiako NP, Interferon: Role in health, current trends and therapeutic potentials, Journal of Drug Delivery and 
Therapeutics. 2020; 10(3):227-230   http://dx.doi.org/10.22270/jddt.v10i3.4005                                                                                                             
*Address for Correspondence:  




When host cells are invaded by several pathogens, which are 
majorly viruses, bacteria, parasites, and tumour cells 
inclusive; host cells respond by releasing a group of signaling 
proteins, known as interferons (IFNs) 1-4. IFNs are 
considered to be cytokines which are protein molecules that 
induce cell-to-cell communication to trigger immunity 
against invading pathogens. Because of their ability to 
"interfere" with the process of viral replication and 
ultimately protecting cells from virus infections, they are 
named interferon. IFNs also act by: activating cells involved 
in immunity, such as macrophages and NK cells (natural 
killer cells); increasing host defenses via inducing foreign 
antigen uptake and increasing the expression of major 
histocompatibility complex (MHC) antigens5. The production 
of IFNs and other cytokines cause certain symptoms 
associated with infections, such as muscle pain, fatigue, fever 
and flu-like “symptoms” 6. In humans and animals, over 20 
distinct interferon genes and proteins have been identified7.  
Currently, interferons are categorized as cytokines under the 
group of interleukins and there are three known types of 
IFNs namely: alpha (α), beta (ß), gamma (ɣ) and Lambda (λ) 
interferon. The IFN-α and IFN-ß are classified under type I 
sub-class, whereas IFN-ɣ is classified under type II sub-
class8. The IFN- λ subtype is poorly understood at this time. 
After cells have been exposed to foreign antigens or agents, 
the cells are stimulated to release these IFNs, which then act 
as functionally modulating proteins, leading to events that 
protect against the invading agents. In order to obtain a 
complete antiviral effect, however, other proteins known as 
‘effector’ proteins must be synthesized and released. 
Therefore, interferons are generally known as “inducer” 
molecules because they act on other proteins which trigger 
an antiviral and/or antiproliferative mechanism9,10. To date 
interferons are characterized by three key features: antiviral 
action, immunomodulatory action and an antiproliferative 
action which have been recently reported 11, 12.  Under 
certain conditions, because of the ability of some IFNs to 
block cells at a given phase of the cell cycle, investigation of 
their antitumour activity has become crucial12. 
TYPES OF INTERFERON 
Alpha interferon 
Alpha interferon, because it is produced by leukocytes, it is 
also named ‘leukocyte interferon’. It is coded for by 15 genes 
and 9 pseudogenes found on human chromosome 9 and 
murine chromosome 413. Each of these genes does not 
contain any intron (non coding region) but only exons (DNA-
coding region) 13. The production of IFN-α is influenced by 
the action of external agents such as tumour or eukaryotic 
cells, or by virus-infected cells; and one crucial point to note 
is that all these inducers trigger the production of IFN-α by 
lymphocytes and macrophages. 
Beta Interferon 
The beta type (IFN-ß) was the first interferon to be 
discovered in 1957 by Isaacs and Lindenmann14.  Isaacs and 
Lindenmann observed that the cells exposed to the dead 
viruses secreted a previously unknown substance which 
blocked future viral attack. IFN-ß is also named ‘fibroblast 
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interferon’ because it is  produced by fibroblasts and 
epithelial cells under the action of foreign nucleic acids like 
viruses or other types. Also, IFN-ß is coded by a gene docked 
on human chromosome 915. In this case, only one gene exists 
and again there are no introns, therefore the whole gene 
codes for the protein.  
Gamma interferon 
The gamma interferon (IFN-ɣ) belongs to a separate sub-
class, called type II interferon that is named ‘immune 
interferon’. The IFN-ɣ is produced especially by lymphocytes 
(activated T cells); and it can promote macrophage 
activation, mediate antiviral and antibacterial immunity, 
enhance antigen presentation, orchestrate activation of the 
innate immune system, coordinate lymphocyte-endothelium 
interaction etc.16,17. IFN-ɣ, like IFN-ß, is also coded by a single 
gene which, however, is not docked on chromosome 9, but 
on chromosome 1218,19. In addition, it contains 3 introns, 
which was not the case with The IFN-α and IFN-ß19. These 
and other features resulted to allocating IFN-ɣ to a separate 
class which has different characteristics with respect to IFN-
α and IFN-ß. Interestingly, another unique trait of IFN-ɣ is 
that it has unstable nature at an acidic pH and these are very 
important characteristics, especially as far as interferon-
based therapy is concerned. 
Lambda interferon  
The lambda interferon (IFN-λ) is classified under the type III 
IFN. It is induced by viruses and other IFNs and displays 
potent antiviral activity against some virus infections in 
vivo20. Acceptance of this classification is less universal than 
that of type I and type II, and unlike the other two, little is 
known of this class and lots of investigations are currently 
ongoing to properly understand it. The type III interferon 
group consists of four IFN-λ (lambda) molecules called IFN-
λ1, IFN-λ2, IFN-λ3 (also known as IL29, IL28A and IL28B 
respectively), and IFN-λ421. 
CLASSIFICATION 
Type I interferon: Are produced in direct response to viral 
infection and comprise the products of the IFN-α multigene 
family, which are predominantly synthesized by leucocytes, 
and the product of the IFN-β gene, which is synthsized by 
most cell types but particularly by fibroblasts. 
Type II Interferon: Consists of the product of the IFN-γ gene 
and, rather than being induced directly by virus infection, is 
synthesized in response to the recognition of infected cells 
by activated T lymphocytes and natural killer (NK) cells 
Type III interferon: The type III interferons are structurally 
more closely related to the IL-10 family of proteins than 
either of the other IFN subtypes, but contribute to antiviral 
responses and induce activation of many of the same genes 
as the type I and II IFN molecules. This subtype is poorly 
understood at this time and has not been studied in graft-
versus-host disease (GVHD) or graft-versus-leukemia (GVL) 
responses. Both type I interferons and IFN-γ play critical 
roles in GVHD and GVL22. 
 
 
MECHANISM OF ACTION OF INTERFERON  
                                                                                         
 
                                                                                                                
 
Figure1: Mechanism of action of interferon: Role of interferon starts after an initial viral attack on target cells. Several cell 
types when infected with virus secrete interferon. The secreted interferon enters the interstitial fluid and blood and binds to 
interferon receptors. This induces synthesis of inhibitory proteins that inhibit progressive or subsequent viral attack and 
possible viral replication 
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THERAPEUTIC APPLICATIONS AND FUNCTIONS OF 
INTERFERON 
Antiviral activity 
Significant successes have been achieved in the wide use of 
recombinant IFN-α forms in the treatment of chronic 
hepatitis B virus (HBV) and hepatitis C virus (HVC) 
infections and some forms of cancer23-25. IFN-β treatment for 
multiple sclerosis is regularly used to limit exacerbations of 
the disease26-28. IFN-γ has been approved for clinical use 
only in a rare congenital disorder and in chronic 
granulomatous disease29,30. 
Antiproliferative and antitumour activities 
Currently, the antiproliferative action, together with its 
antitumour activity, is one major breakthrough concerning 
interferon function31-35. It is known that IFN-α can act on T-
cells causing the differentiation of the T-helper 1 cells, while 
at the same time inhibiting the growth of other 
lymphocytes34. Similarly, IFN-α can act on NK cells and 
macrophages, thus enhancing their production of interferon 
and especially their production of interleukin 1 and their 
proliferation, thus increasing the number of circulating 
cells36. 
Because of their cell differentiation and growth regulatory 
properties, interferons have been used in attempts to treat 
neoplasms37,38. Several forms of haematological cancers and 
solid tumours have been treated with interferons with some 
success33,34. 
Treatment of multiple sclerosis 
Treatment of multiple sclerosis with IFN-β was initiated 
based on the immunomodulatory properties of the 
interferon39,40. Well-controlled studies have demonstrated 
that intramuscular treatment with IFN-β results in a 
reduction in the annual rate of relapses of multiple 
sclerosis41. 
Signal transduction 
To exert their first messenger activities, IFNs bind to specific 
membrane receptors. These receptors enables cells sense 
the external signal of IFN and then transfer it in the interior, 
so that the cell can produce what is known as interferon-
inducible proteins42. Just like the interferons, receptors are 
classified into two, namely the receptor for IFN-α and IFN-ß 
on the one side and the receptor of IFN-ɣ on the other side43.  
The interferon receptors consist of two sub-units. These are 
transmembrane proteins with an extra-cytoplasmic domain 
and an intra-cytoplasmic domain displaying particular 
motifs that bind to proteins which make it possible for this 
external signal to be sensed within the cell44. These 
receptors are grouped under the JAK proteins, which mainly 
comprise the tyrosine kinase proteins that can 
phosphorylate tyrosine residues44.  The STAT proteins are 
other important proteins, and they too have dual role; i.e. 
they act as signal transducers and also as transcription 
activators45. Finally, another group of proteins playing a 
pivotal role in the interferon signal transduction is 
composed by the Interferon Regulatory Factors (IRFs), 
known to act as transcription factors  but are still being 
studied to fully understand their functional roles or 
mechanisms46,47.  
SIDE EFFECTS OF INTERFERONS 




- muscle pains 
- Cardiorenal toxicity, bone marrow and liver toxicities. 
48-50 
CONCLUSION  
Interferon is gaining significance based on clinical and 
laboratory results and the availability of improved molecular 
technology. Therapeutic application of interferon 
applications can be envisaged in all areas of biomedical 
sciences, including molecular biology techniques. Hence the 
usefulness of interferon continues to expand into the field of 
medicine, molecular biology, pharmaceutical medicine and 
biotechnology. 
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